Bevacizumab Added to Erlotinib Increases PFS in NSCLC
June 6th 2014The addition of bevacizumab to erlotinib as first-line therapy yielded a significantly extended progression-free survival in patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC), according to a new phase II study.
HPV-Targeting Immunotherapy Shows Early Promise in Cervical Cancer
June 2nd 2014Two patients with metastatic cervical cancer achieved durable complete responses that have so far lasted from 15 to 22 months through an adoptive T-cell therapy (ACT) targeting the human papillomavirus (HPV) in a study that researchers say supports the concept that the experimental immunotherapy approach may be beneficial in a variety of tumor types.
Hyperfractionated Radiation Therapy: Improved Local-Regional Control and OS in HNSCC
May 2nd 2014Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity.
Researchers Focus on Optimizing Radiotherapy for Locally Advanced NSCLC
April 24th 2014Locally advanced non-small cell lung cancer (NSCLC) remains a challenging disease to treat, with a 5-year survival rate for patients with unresectable stage III disease of approximately 20%, even after definitive radiation therapy and concurrent chemotherapy.
(P063) Multiple Course Stereotactic Ablative Body Radiotherapy for Non–Small-Cell Lung Cancer
April 15th 2014Technical advances in radiotherapy (RT), especially stereotactic ablative body radiotherapy (SABR), have allowed many non–small-cell lung cancer patients once considered untreatable to be eligible for locally effective therapies. Some patients will experience recurrence or will present with multiple lung primaries. We review the success and impact of SABR in patients who have undergone multiple course therapy.
(S043) RadiotypeDx: Validation of a Radiation Sensitivity Signature in Human Breast Cancer
April 15th 2014An unmet clinical need in breast cancer (BC) management is the identification of which patients will respond to radiation therapy (RT). We hypothesized that the integration of post-RT clonogenic survival data with gene expression data across a large spectrum of BC cell lines would generate a BC-specific RT sensitivity signature predictive for RT response in BC patients and allow identification of patients with tumors refractive to conventional therapy.
(P069) Stereotactic Body Radiotherapy for T1 Versus T2 Non–Small-Cell Lung Cancers
April 15th 2014Stereotactic body radiation therapy (SBRT) has become the treatment of choice for early-stage non–small-cell lung cancers (NSCLCs) in nonoperative candidates. The purpose of this study was to examine the efficacy and toxicity of SBRT for stage T2 NSCLC.
Biomarkers that Can Predict Resistance to Radiation Therapy Identified in HNSCC
March 28th 2014The effectiveness of radiation treatments for patients with squamous cell cancer of the head and neck has been reviewed by an international team of researchers. They identified two biomarkers that were good at predicting a patient's resistance to radiation therapy. "While our findings are encouraging, and a step toward personalized medicine, we hope to do more of this research with a larger, randomized trial," the authors conclude.
The Place of Transplantation in Mantle Cell Lymphoma
October 15th 2013The role of transplant in MCL is in clinical evolution. Up-front high-dose therapy and autologous stem cell transplant remains an attractive option for those with chemosensitive disease regardless of the induction regimen chosen, whereas this approach in the relapsed or refractory setting has not yielded long-term disease-free intervals.
Do Oncogenic Drivers Exist in Squamous Cell Carcinoma of the Lung?
September 16th 2013The Cancer Genome Atlas provides us with our first thorough insight into the genetic heterogeneity of squamous cell carcinoma of the lung; whether these findings will translate into personalized squamous cell lung cancer therapy is yet to be determined.